PURIDIFY WAS ACQUIRED BY GE HEALTHCARE, NOW CYTIVA IN 2017 Global demand for cheaper biotherapeutics drives the need for bioprocessing cost reduction, a significant proportion of which comes from chromatography reagents and their operation. • Puridify uses nanofibre technology to create purification solutions for biotherapeutic manufacturing. • Puridify's chromatography reagent, FibroSelect, reduces bioprocessing costs for manufacturers. • FibroSelect offers substantial productivity increase in purification whilst making minimal changes to current best practice. Please visit our website for more information: www.puridify.com